| Excerpt | Reference |
|---|
| "The gene for sickle cell disease is carried by 8% of the African-American population in the United States." | ( Pollack, CV; Sanders, DY; Severance, HW, 1992) |
| "Sickle cell disease is a health priority." | ( Mérault, G; Reinette, P; Rosa, J; Zohoun, IS, 1992) |
| "The treatment of sickle cell disease is still mainly symptomatic." | ( Aluoch, JR, 1991) |
| "Sickle cell disease is the first case of aminophospholipid translocase pathology." | ( Beuzard, Y; Blumenfeld, N; Devaux, PF; Galacteros, F; Zachowski, A, 1991) |
| "Sickle cell disease is statistically more prevalent among the host population than is phenylketonuria (10-12:100,000), hypothyroidism (20:100,000) and cystic fibrosis (62-63:100,000) in the general population." | ( France-Dawson, M, 1986) |
| "Sickle cell anemia is the most frequent etiology of osteonecrosis there." | ( Bloch, P; Genin, P; Vouge, M, 1985) |
| "The treatment of sickle cell disease is still primarily symptomatic." | ( Aluoch, JR, 1983) |
| "Sickle cell disease is associated with impaired urinary potassium excretion, but renal potassium handling in patients with HbAS has not been reported." | ( Lanier, DC; Oster, JR; Vaamonde, CA, 1980) |
| "Two patients with sickle cell anemia are reported who developed relative impotence after repeated episodes of priapism." | ( Barton, JC; Conrad, ME; Durant, JR; Perrine, GM, 1980) |
| "Sickle cell disease is associated with cerebral hyperemia, which is therapeutically reduced by transfusion; however, the process of transfusion-induced cerebral perfusion changes has heretofore not been observed." | ( Hurlet, A; Mohr, JP; Piomelli, S; Prohovnik, I; Venketasubramanian, N, 1994) |
| "Sickle cell disease is enormously variable in its expression and outcome." | ( Serjeant, BE; Serjeant, GR, 1993) |
| "Children with sickle cell disease are at increased risk for bacterial sepsis and, when febrile, are usually hospitalized for intravenous antibiotic therapy pending results of blood cultures." | ( Dancy, RM; Day, SW; Harris, SC; Wang, WC; Wilimas, JA; Williams, LL, 1996) |
| "Sickle cell anemia is the most common heritable hematological disease, yet no curative treatment exists for this disorder." | ( Howrey, RP; Lan, N; Lee, SW; Smith, CA; Sullenger, BA, 1998) |
| "Sickle cell anemia is a monogenic hereditary disease characterized by a mutation in the beta globin gene." | ( Ayadi, H; Fakhfakh, F; Frikha, M; Gargouri, J; Ghali, L; Harrabi, M; Labiadh, Z; Mseddi, S; Souissi, T, 1998) |
| "Sickle cell disease is an autosomal recessive disease that primarily affects persons of African ancestry." | ( Atweh, GF; Cashman, TD; Davis, WT; Sutton, M, 1999) |
| "Sickle cell disease is prevalent in this area and most cases present before 5 year of age." | ( Chatruvedi, P; Kamble, M, 2000) |
| "Sickle cell anemia is characterized by painful vaso-occlusive crises." | ( Belcher, JD; Hebbel, RP; Marker, PH; Vercellotti, GM; Weber, JP, 2000) |
| "Sickle cell anemia is a severe disorder that rarely spares affected adults." | ( Corbisier, C; Faron, G; Tecco, L; Vokaer, A, 2001) |
| "Sickle cell anemia is a genetic blood disorder arising from a point mutation in the beta-globin gene that leads to the replacement of glutamic acid residue by valine at the sixth position of the beta--chain of hemoglobin." | ( Mehanna, AS, 2001) |
| "Sickle cell disease is a recessively inherited condition in which synthesis of haemoglobin is abnormal." | ( , 2001) |
| "Sickle cell disease is a congenital haemolytic anaemia which is frequent in people of African origin." | ( Dresse, MF, 2002) |
| "Sickle cell disease is observed to occur in significantly high frequencies amongst the tribes of India." | ( Babu, BV; Kusuma, YS; Leela, BL, 2002) |
| "Sickle cell disease is an inherited disorder of haemoglobin, which results in abnormal red blood cells." | ( De Franceschi, L; Riddington, C, 2002) |
| "Sickle cell disease is a serious and life threatening disease that affects approximately 1 in 600 African-Americans." | ( Fixler, J; Styles, L, 2002) |
| "Sickle cell disease is characterized by microvascular occlusion and hemolytic anemia, factors that impair tissue oxygen delivery." | ( Cannon, RO; Gladwin, MT; Levin, IW; Zuzak, KJ, 2003) |
| "Sickle cell disease is characterized by chronic hemolytic anemia and vaso-occlusive painful crisis." | ( Ahmed, S; Kimpo, M; Mattana, J; Russo, L; Siddiqui, AK; Siddiqui, RK, 2003) |
| "Sickle cell disease is numerically as common as thalassaemia." | ( Agarwal, MB, 2003) |
| "Sickle cell anemia is characterized by the presence of dense dehydrated erythrocytes that have lost most of their K content." | ( Brugnara, C, 2003) |
| "Sickle cell disease is considered protective against large vessel coronary artery disease." | ( Sherman, SC; Sulé, HP, 2004) |
| "Severity of sickle cell disease is variable, and treatment is usually symptomatic." | ( Anie, KA; Chinegwundoh, F, 2004) |
| "Sickle cell disease is characterized by a state of nitric oxide resistance and limited bioavailability of l-arginine, the substrate for nitric oxide synthesis." | ( Blackwelder, WC; Gladwin, MT; Hazen, SL; Kato, GJ; Morris, CR; Morris, SM; Poljakovic, M; Sachdev, V; Vichinsky, EP; Wang, X, 2005) |
| "Sickle cell anemia is one of the most common genetic diseases worldwide." | ( Chang, JC; Kan, YW; Ye, L, 2006) |
| "Sickle cell disease is a systemic disorder that is caused by a mutation (Glu6Val) in the gene that encodes beta globin." | ( Steinberg, MH, 2006) |
| "Sickle cell disease is an inherited genetic disorder characterized by an abnormality of haemoglobin that predisposes to polymerization and consequent deformation ("sickling")." | ( Bennett, KC; Dunlop, RJ, 2006) |
| "Children with sickle cell disease are at risk of developing neurologic complications, including stroke, transient ischemic attack, seizures, coma, and a progressive reduction in cognitive function." | ( Adams, RJ; Datta, AK; DeBaun, MR; Kirkham, FJ; Lerner, NB; Noetzel, M; Rees, DC, 2006) |
| "Sickle cell disease is characterized by vaso-occlusive episodes, mainly in the small vessels, resulting in tissue ischemia, multi-organ failure, and, occasionally, death." | ( Athanassiou, G; Kourakli, A; Moutzouri, A; Zoumbos, N, 2006) |
| "Sickle cell anemia is the most common heritable hematological disease affecting humans." | ( Karimi, M; Mosavizadeh, K; Mousavizadeh, K; Sharifzadeh, S; Zekavat, OR, 2006) |
| "Sickle cell anemia is a common genetic disorder in African Americans." | ( Hebbel, RP; Lunzer, MM; Portoghese, PS; Yekkirala, A, 2007) |
| "Sickle cell disease is one of the most common genetic disorders." | ( Al Hajeri, AA; Fedorowicz, Z; Omran, A; Tadmouri, GO, 2007) |
| "Sickle cell anemia is an inherited disorder caused by abnormal hemoglobin, the S hemoglobin." | ( Balci, TA; Canatan, D; Cerci, C; Cerci, SS; Ozbek, FM; Suslu, H; Yesildag, A; Yildiz, M, 2007) |
| "Sickle cell disease is an inherited disorder of haemoglobin, which results in abnormal red blood cells." | ( Ballas, SK; Singh, PC, 2007) |
| "Sickle cell disease is associated with considerable morbidity and premature mortality." | ( Krishnamurti, L, 2007) |
| "Pain in adults with sickle cell disease is the rule rather than the exception and is far more prevalent and severe than previous large-scale studies have portrayed." | ( Aisiku, IP; Bovbjerg, VE; Dahman, B; Levenson, JL; McClish, DK; Penberthy, LT; Roberts, JD; Roseff, SD; Smith, WR, 2008) |
| "Sickle cell disease is a disorder that produces significant morbidity and mortality." | ( Khosla, A; Ponsky, TA, 2008) |
| "Sickle cell disease is the most common inherited disease in the U." | ( Howard, J; Olujohungbe, A, 2008) |
| "The root cause of sickle cell disease is a single beta-globin gene mutation coding for the sickle beta-hemoglobin chain." | ( Steinberg, MH, 2008) |
| "Sickle cell disease is characterized by altered blood rheology due to a reduced haematocrit and a resulting lowered viscosity." | ( Bowers, AS; Pepple, DJ; Reid, HL, 2008) |
| "Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells." | ( Ballas, SK; Nagalla, S, 2010) |
| "Sickle cell anemia is accompanied by the activation of coagulation and thrombosis." | ( Abdulla, F; Hebbel, RP; Kelm, RJ; Kollander, R; Milbauer, LC; Solovey, A, 2010) |
| "Sickle cell disease is very variable with many patients leading full lives with long periods with little or no pain." | ( Ahmedzai, SH; Wright, J, 2010) |
| "Sickle cell anemia is the most common hemoglobinopathy worldwide; its musculoskeletal complications consist more often of medullary infarctions involving long bones." | ( Bellagha, I; Ben Hassine, L; Bouguila, H; Chebbi, A; Douira-Khomsi, W; Jarraya, M; Lahmar, L; Louati, H, 2010) |
| "Sickle cell disease is characterized by painful vaso-occlusive crises during which abnormal interactions between erythroid adhesion molecules and vessel-wall proteins are thought to play a critical role." | ( Bachir, D; Bartolucci, P; Chaar, V; Colin, Y; El Nemer, W; Fauroux, C; Galactéros, F; Habibi, A; Le Van Kim, C; Picot, J, 2010) |
| "Sickle cell disease is caused by one of the 1200 known hemoglobin variations." | ( Hess, S; Hüttenhain, R, 2010) |
| "Sickle cell disease is a single amino acid molecular disorder of hemoglobin leading to its pathological polymerization, red cell rigidity that causes poor microvascular blood flow, with consequent tissue ischemia and infarction." | ( Ballas, SK; Eckman, J; Minniti, CP; Sebastiani, P; Steinberg, MH, 2010) |
| "Sickle cell disease is still associated with high morbidity and mortality but clinical care has improved and no death has occurred in the last 10 years." | ( Cotton, F; Dedeken, L; Dresse, MF; Ferster, A; Gulbis, B; Heijmans, C; Ketelslegers, O; Lê, PQ; Vanderfaeillie, A; Vermylen, C; Vertongen, F, 2010) |
| "Patients with sickle cell anemia are at risk for organ damage including kidney disease." | ( Askenazi, DJ; Hilliard, LM; Howard, TH; Johnson, SM; Lebensburger, J; Rozario, NL, 2011) |
| "Children with sickle cell anemia are at risk for brain injury." | ( Fineberg, NS; Hilliard, LM; Howard, TH; Lebensburger, JD; McGrath, TM, 2011) |
| "Sickle cell disease is characterized by phenotypic heterogeneity and many genetic modifiers have been identified with elevated Hb F being the most recognized ameliorating factor." | ( Adekile, AD, 2011) |
| "Since patients with sickle cell disease are particularly vulnerable to the effects of periods of hypoxia, which may produce significant morbidity, and because of the additional practical challenges in sedating this group of patients, intravenous sedation should be undertaken in a specialist unit." | ( Boyle, C; Bryant, C, 2011) |
| "Sickle cell disease is a public health problem." | ( Burny, F; Burny, ME; Donkerwolcke, M; Etienne-Julan, M; Mukisi-Mukaza, M; Saint Martin, C, 2011) |
| "Sickle cell anemia is characterized by chronic hemolysis coupled with extensive vascular inflammation." | ( Gao, G; Howard, T; Hu, Y; Johnson, M; Lebensburger, JD; Persons, DA; Pestina, TI; Rosch, JW; Tuomanen, EI; Ware, RE; Zakharenko, SS, 2012) |
| "Hemoglobin sickle cell disease is one of the most frequent hemoglobinopathies." | ( Avellino, V; Girot, R; Grateau, G; Hammoudi, N; Haymann, JP; Lionnet, F; Stojanovic, KS, 2012) |
| "Sickle cell anemia is an inherited hematologic disorder associated with hemolytic and vaso-occlusive complications." | ( Chantrathammachart, P; Pawlinski, R, 2012) |
| "Sickle cell anemia is a disease caused by a defect in red blood cells, which among other things can cause vasooclusive crisis." | ( Baker, NC; Blanco, V; Craft, N; Garcerant, D; Martinez, J; Rubiano, L, 2012) |
| "Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells." | ( Ballas, SK; Nagalla, S, 2012) |
| "Sickle cell disease is a genetic disorder of hemoglobin synthesis leading to a deformation of the red blood cell." | ( Alavi, A; Bazakas, A; Ladizinski, B; Mistry, N; Salcido, R; Sibbald, RG, 2012) |
| "Sickle cell anemia is a disease that can cause arthritis of the temporomandibular joint, and although it is rare, clinicians should be attentive to the differential diagnosis in patients with this disease." | ( Caracas, Mda S; da Silva Castro, JC; de Siqueira, JT; Fonseca, GH; Gualandro, SF; Jales Neto, LH; Jales, SP; Suganuma, LM, 2013) |
| "Sickle cell disease is the commonest haemoglobinopathy in Africa, the Middle East and India." | ( Ballardini, E; Bernardoni, R; Bigoni, S; Borgna-Pignatti, C; Carandina, G; Ferlini, A; Garani, G; Guerra, G; Marsella, M; Melandri, C; Patella, A; Ravani, A; Tarocco, A; Zucchelli, M, 2013) |
| "Sickle cell disease is a common inherited autosomal disease that is characterised by abnormally shaped (sickle-shaped) red blood cells (RBCs)." | ( Guru, KN; Moghe, S; Nair, PP; Pillai, A, 2012) |
| "Sickle cell anemia is a genetically inherited disease in which the "SS" individual possesses an abnormal beta globin gene." | ( Imaga, NA, 2013) |
| "β-thalassemia and sickle cell disease are hemoglobinopathies with reduced/absent β chains in the former and dysfunctional β chains in the latter." | ( Abroun, S; Ahmadvand, M; Chegeni, R; Fard, AD; Hajifathali, A; Kaviani, S; Mohammadi, MM; Noruzinia, M; Saki, N; Soleimani, M; Zonoubi, Z, 2013) |
| "Sickle cell disease is a group of disorders characterized by deformation of erythrocytes." | ( Ballas, SK; Nagalla, S; Sasongko, TH, 2013) |
| "Sickle cell disease is the most common inherited haematological disorder that leads to the irreversible damage of multiple organs." | ( Pawlinski, R; Sparkenbaugh, E, 2013) |
| "Sickle cell disease is one of the most common and severe genetic disorders in the world." | ( Fedorowicz, Z; van Zuuren, EJ, 2013) |
| "Sickle cell disease is a very common entity in central India, especially in Maharashtra." | ( Aher, A; Khot, R, 2012) |
| "Sickle cell disease is an inherited blood disorder that affects red blood cells." | ( Devine, BP, 2013) |
| "Pregnancy in sickle cell disease is associated with increased risk of maternal and fetal morbidity and mortality." | ( Dave, A; Khandelwal, S; Kumar, R; Natu, N, 2014) |
| "Patients with sickle cell disease are known to have recurrent lower extremity ulcers that have a high pain score and are resistant to conventional means of wound therapy." | ( Baroud, J; Barritault, D; Dibo, S; Hayek, S; Ibrahim, A, 2016) |
| "Sickle cell disease is an inherited blood disorder characterized by chronic hemolytic anemia and episodic vaso-occlusive pain crises." | ( Ackerman, H; Anaebere, TC; Antalek, MD; Conrey, AK; Gorbach, AM; Ikeda, AK; Kato, GJ; Mendelsohn, L; Nichols, J; Rowley, CA; Seamon, C; Seidel, M, 2014) |
| "Sickle cell disease is associated with a decreased life expectancy, half of the deaths occurring in the ICU." | ( Cecchini, J; Djibré, M; Fartoukh, M; Girot, R; Lionnet, F; Parrot, A; Stojanovic, KS, 2014) |
| "The prevalence of Sickle cell disease is extremely high in Democratic Republic of Congo." | ( Aloni, MN; Ekila, MB; Gini-Ehungu, JL; Lepira, FB; Ngiyulu, RM; Nseka, NM; Nsibu, CN, 2014) |
| "Sickle cell disease is one of the most common and severe genetic disorders in the world." | ( Fedorowicz, Z; van Zuuren, EJ, 2014) |
| "Sickle cell anemia is an inherited disorder of hemoglobin that leads to a variety of acute and chronic complications." | ( Cheung, A; DeCastro, L; Flanner, H; Kramer, W; Kuypers, F; Magnani, JL; Rhee, S; Styles, L; Telen, MJ; Thackray, H; Wun, T, 2014) |
| "Sickle cell disease is an inherited disorder of the blood, and characterized by vasoocclusive crises (VOC), risks for pneumococcal infections and organ toxicities, is associated with morbidity and premature mortality." | ( Agarwal, A; Arjunan, A; Dani, A; Gettig, E; Krishnamurti, L; Shrikhande, AV; Tijare, J, 2014) |
| "Sickle cell anemia is a life-threatening disease, and the most common genetic disease in the world." | ( Ågren, A; Kjellander, C; Sennström, MK; Stiller, V, 2015) |
| "Sickle cell disease is a collection of autosomal recessive genetic disorders." | ( Ajuwon, MD; Benneh, AA; Olayemi, E, 2014) |
| "The anemia of sickle cell disease is associated with a severe inflammatory vasculopathy and endothelial dysfunction, which leads to painful and life-threatening clinical complications." | ( Andolfo, I; Brugnara, C; Cimino, J; De Franceschi, L; Federti, E; Ghigo, A; Hirsch, E; Iolascon, A; Kalish, BT; Matte, A; Puder, M; Siciliano, A; Weinberg, O, 2015) |
| "Sickle cell anemia is associated with compromised oxygen-carrying capability of hemoglobin and a high incidence of overt and silent stroke." | ( Barker, S; Clark, CA; Clayden, JD; Cox, TC; Edey, R; Hollocks, MJ; Kawadler, JM; Kirkham, FJ; Robins, A; Seymour, EL; Telfer, P; Wilkey, O, 2015) |
| "Sickle cell anemia is a blood disorder, known to affect the microcirculation and is characterized by painful vaso-occlusive crises in deep tissues." | ( Abkarian, M; Loiseau, E; Martinez, PA; Massiera, G; Mendez, S, 2015) |
| "Sickle cell disease is a group of disorders characterized by deformation of erythrocytes." | ( Ballas, SK; Nagalla, S; Sasongko, TH, 2015) |
| "Sickle cell anemia is one of the most common genetic blood disorders worldwide." | ( DeBaun, MR; Rebele, EC; Stimpson, SJ, 2016) |
| "Sickle cell anemia is an inherited blood disorder that is characterized by painful vaso-occlusive crises, for which there are few treatment options." | ( Abboud, MR; Agbenyega, T; Brown, PB; Colombatti, R; Hassab, HM; Heath, LE; Heeney, MM; Hoppe, CC; Inusa, B; Jakubowski, JA; Kanter, J; Nduba, VN; Ogutu, B; Oyieko, JN; Rees, DC; Robitaille, N; Segbefia, CI; Zamoryakhin, D; Zhou, C, 2016) |
| "Sickle cell disease is a class of hemoglobinopathy in humans, which is the most common inherited disease in the world." | ( Canet-Soulas, E; Chirico, EN; Connes, P; Faës, C; Martin, C; Pialoux, V, 2016) |
| "Sickle cell disease is one of the most common and severe genetic disorders in the world." | ( Fedorowicz, Z; van Zuuren, EJ, 2015) |
| "Sickle cell disease is a hereditary hemoglobinopathy characterized by abnormal hemoglobin production, hemolytic anemia, and intermittent occlusion of small blood vessels, leading to tissue ischemia, chronic organ damage, and organ dysfunction including endocrine organs." | ( Abo El-enein, AM; El-Farargy, MS; Elrefaey, S; Hagag, AA, 2016) |
| "Patients with sickle cell disease are at risk for vaso-occlusive crises, when the abnormally shaped red blood cells aggregate and block the capillaries." | ( Boiy, T; Claeys, L; Janssens, C; Maes, P; Wojciechowski, M, 2015) |
| "Gene therapy for sickle cell disease is currently in active trials." | ( Billett, HH; Branch, C; Choi, E; Cui, MH; Mohandas, N; Shi, PA; Yazdanbakhsh, K, 2016) |
| "Sickle cell disease is one of the most common genetic disorders." | ( Al Hajeri, A; Fedorowicz, Z, 2016) |
| "Sickle cell disease is a group of disorders that affects haemoglobin, which causes distorted sickle- or crescent-shaped red blood cells." | ( Abas, AB; Dixit, R; Madan, SS; Nettem, S; Soe, HH; Stover, PJ; Vance, LD, 2016) |
| "Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells." | ( Ballas, SK; Nagalla, S, 2016) |
| "Sickle cell disease is fundamentally a kinetic disorder, in which cells containing the mutated hemoglobin (hemoglobin S; HbS) will cause occlusion if they sickle in the microvasculature, but have minimal (or no) consequences if they sickle in the venous return." | ( Aprelev, A; Ferrone, FA; Rotter, M; Yosmanovich, D, 2016) |
| "Sickle cell disease is a genetic haemoglobin disorder, which can cause severe pain, significant end-organ damage, pulmonary complications, and premature death." | ( Cho, G; Estcourt, LJ; Fortin, PM; Hambleton, IR; Hopewell, S; Trivella, M, 2016) |
| "Sickle cell disease is a destructive genetic disorder characterized by the formation of fibrils of deoxygenated hemoglobin, leading to the red blood cell (RBC) morphology changes that underlie the clinical manifestations of this disease." | ( Boudreau, R; Chiu, W; Cinquin, BP; Darrow, MC; Larabell, CA; Rochat, RH; Schmid, MF; Smith, EA; Xia, Y; Zhang, Y, 2016) |
| "The hallmark of sickle cell disease is the polymerization of sickle haemoglobin due to a point mutation in the β-globin gene (HBB)." | ( Abdulmalik, O; Kato, GJ; Oder, E; Safo, MK, 2016) |
| "Sickle cell disease is a single point mutation disease that is known to alter the coagulation system, leading to hypercoagulable plasma conditions." | ( Averett, RD; Fan, NK; Norton, DG; Platt, MO, 2017) |
| "Sickle cell disease is probably the first known assembly disease, and its mechanism has been extensively studied." | ( Ferrone, FA, 2016) |
| "Sickle cell disease is the most common hemoglobin variant in the world and can present with recurrent vaso-occlusive painful crises." | ( Hagedorn, JM; Monico, EC, 2019) |
| "Sickle cell disease is a frequent genetic anomaly characterized by altered molecular structure of hemoglobin resulting into crescent-like deformation of the red blood corpuscles." | ( Chaudhari, H; Goyal, S; Patil, C, 2016) |
| "Sickle cell disease is one of the commonest severe monogenic disorders in the world, due to the inheritance of two abnormal haemoglobin (beta globin) genes." | ( Estcourt, LJ; Fortin, PM; Hopewell, S; Trivella, M; Wang, WC, 2017) |
| "Sickle cell disease is a genetic chronic haemolytic and pro-inflammatory disorder." | ( Abas, AB; Ni, H; Osunkwo, I; Said, AR; Singh, J; Soe, HH; Than, NN, 2017) |
| "Sickle cell disease is a common and life-threatening haematological disorder that affects millions of people worldwide." | ( Abboud, MR; de Montalembert, M; Tshilolo, L; Ware, RE, 2017) |
| "Sickle cell disease is an autosomal recessive inherited haemoglobinopathy which causes painful vaso-occlusive crises due to sickle red blood cell dehydration." | ( Abas, AB; De Franceschi, L; Palaniappan, SK; Soe, HHK; Than, NN, 2017) |
| "Patients with sickle cell disease are at high risk for chronic hepatitis C infection." | ( Brainard, DM; Hyland, RH; Lanzkron, S; McHutchison, JG; Moon, J; Sulkowski, M; Zhang, F, 2017) |
| "Sickle cell disease is caused by a mutant form of hemoglobin that polymerizes under hypoxic conditions, increasing rigidity, fragility, calcium influx-mediated dehydration, and adhesivity of red blood cells." | ( Alexander-Miller, MA; Basu, S; Bolden, CA; Buechler, NL; Caudell, DL; Gladwin, MT; Jailwala, A; Kim, HW; Kim-Shapiro, DB; Ostrowski, D; Perlegas, A; Rahbar, E; Vachharajani, V; Wajih, N, 2017) |
| "Severity of sickle cell disease is variable, and treatment is usually symptomatic." | ( Anie, KA; Chinegwundoh, FI; Smith, S, 2017) |
| "Sickle cell disease is characterized by chronic anemia and vaso-occlusive crises, which eventually lead to multi-organ damage and premature death." | ( André-Schmutz, I; Cavazzana, M; Couzin, C; Delville, M; Félix, T; Gabrion, A; Joseph, L; Lagresle-Peyrou, C; Lamhaut, L; Lefrère, F; Magnani, A; Magrin, E; Miccio, A; Plantier, C; Ribeil, JA; Romano, O; Sadek, H; Stanislas, A; Ternaux, B; Tréluyer, JM; Weber, L, 2018) |
| "Sickle cell disease is associated with acute painful episodes and chronic intractable pain." | ( Atianjoh, FE; Fox, BM; Gu, X; Li, Z; Lutz, BM; Pollock, DM; Tao, YX; Wu, S, 2018) |
| "Sickle cell disease is caused by a mutant form of hemoglobin that polymerizes under hypoxic conditions which leads to red blood cell (RBC) distortion, calcium-influx mediated RBC dehydration, increased RBC adhesivity, reduced RBC deformability, increased RBC fragility, and hemolysis." | ( Gladwin, MT; Kim-Shapiro, DB, 2018) |
| "Sickle cell disease is an inherited disorder of hemoglobin (Hb)." | ( Abdulmalik, O; Berra, L; Bloch, DB; Chen, Q; Cooper, MK; Ferrari, M; Klings, ES; Liu, C; Musayev, FN; Nakagawa, A; Safo, MK; Safo, RS; Schleifer, G; Yu, B; Zapol, WM, 2018) |
| "Although homozygous sickle cell disease is often clinically severe, the corresponding heterozygous state, sickle cell trait, is almost completely benign despite the fact that there is only a modest difference in sickle hemoglobin levels between the two conditions." | ( Chaudhury, A; Higgins, JM; Lu, X; Wood, DK, 2018) |
| "Sickle cell anemia is an autosomal recessive hemoglobinopathy associated with erythrocytes sickling, vaso-occlusive crisis (VOC), as well as multi-organ failure and death." | ( Jha, AN; Lakkakula, BVKS; Mishra, H; Pandey, I; Verma, HK, 2018) |
| "Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells." | ( Ballas, SK; Nagalla, S, 2018) |
| "Evolution of sickle cell disease is marked by the occurrence of acute complications, some of which are real emergencies that can give rise to life-threatening or functional cosequences." | ( Anani, L; Baglo, T; Dodo, R; Mehou, J; Zohoun, A, 2018) |
| "Sickle cell disease is a genetic disorder of haemoglobin causing myriad of pathology including anaemia." | ( Dangana, A; Erhabor, O; Erhabor, T; Ogar, K, 2019) |
| "Sickle cell anemia is the commonest genetic disorder in India, and the frequency of the sickle cell gene is very high in the remote tribal areas where facilities are generally limited." | ( Colah, RB; Dave, K; Desai, S; Italia, Y; Jain, D; Mehta, PR; Mukherjee, MB; Raicha, B; Serrao, E; Shinde, N, 2020) |
| "Sickle cell disease is induced by a mutation that converts normal adult hemoglobin to sickle hemoglobin (HbS) and engenders intracellular polymerization of deoxy-HbS and erythrocyte sickling." | ( Karniadakis, GE; Li, H; Li, X; Li, Z; Lu, L; Vekilov, PG, 2019) |
| "Sickle cell disease is an autosomal recessive inherited haemoglobinopathy which causes painful vaso-occlusive crises due to sickle red blood cell dehydration." | ( Abas, AB; De Franceschi, L; Palaniappan, SK; Soe, HHK; Than, NN, 2019) |
| "Sickle cell disease is a uniquely complex painful disease, with lifelong episodes of unpredictable acute pain and superimposed chronic pain in adulthood." | ( Carroll, CP, 2020) |
| "sickle cell disease is a genetic disease with autosomal inheritance associated with haemoglobin structure abnormality which causes the formation of hemoglobin S." | ( Banza, MI; Cabala, VPK; Lire, LI; Mulefu, JP; N'dwala, YTB; Tshiamala, IB, 2019) |
| "Sickle cell disease is a genetic disorder associated with a single mutation (Glu-β6 → Val-β6) in the β chains of hemoglobin, causing the polymerization of deoxygenated sickle cell hemoglobin (deoxy-HbS)." | ( Galamba, N, 2019) |
| "Sickle cell disease is an autosomal recessive disorder with significant global impact." | ( Kimrey, S; Saving, KL, 2020) |
| "Severity of sickle cell disease is variable, and treatment is usually symptomatic." | ( Anie, KA; Chinegwundoh, FI; Smith, S, 2020) |
| "Sickle cell disease is associated with numerous symptoms and complications." | ( Conrad, R; Emmert, D; Mücke, M; Rasche, T; Seidel, H; Sellin, J, 2020) |
| "Sickle cell disease is an inherited disorder that affects more than 100,000 individuals in the United States and results in a shortened life span." | ( Fantasia, HC; Morse, BL, 2020) |
| "The pathology of sickle cell disease is caused by polymerization of the abnormal hemoglobin S upon deoxygenation in the tissues to form fibers in red cells, causing them to deform and occlude the circulation." | ( Bartolucci, P; Cellmer, T; Dunkelberger, EB; Eaton, WA; Galactéros, F; Ghirlando, R; Henry, ER; Hofrichter, J; Li, Q; Louis, JM; Metaferia, B; Moutereau, S; Ostrowski, D; Thein, SL, 2020) |
| "Sickle cell disease is one of the commonest severe monogenic disorders in the world, due to the inheritance of two abnormal haemoglobin (beta globin) genes." | ( Estcourt, LJ; Hopewell, S; Kohli, R; Trivella, M; Wang, WC, 2020) |
| "Sickle cell disease is associated with frequent vaso-occlusive episode and emergency department visits." | ( Alexander, A; Bonnabeau, E; Bulgin, D; Frederick, E; Rains, G; Shah, N; Tanabe, P; Young, M, 2021) |
| "Sickle cell disease is a group of diseases inherited through the gene and it affects the haemoglobin in the red blood cell." | ( Egba, SI; Ikechukwu, EL; Okafor, PN, 2020) |
| "Sickle cell anemia is hallmarked by hemolysis, which releases hemoglobin (Hb) into the plasma promoting vaso-occlusive crisis (VOC)." | ( Das, K; Das, P; Dash, BP; Dehury, S; Jit, BP; Meher, S; Mohanty, PK; Mohapatra, MK; Patel, S; Sahoo, S, 2021) |
| "Sickle cell disease is the most common hemoglobinopathy and affects millions worldwide." | ( Almeida, LE; Hallmark, L; Kamimura, S; Quezado, ZM; Smith, M, 2021) |
| "Sickle cell disease is an inherited genetic disorder that causes anemia, pain crises, organ infarction, and infections in 13 million people worldwide." | ( Anani, WQ; Ashwood, C; Ashwood, HE; Gundry, RL; Hoffmeister, KM; Schmidt, AP, 2021) |
| "Sickle cell disease is an inherited blood disorder with reduced blood-carrying capacity." | ( Harnisch, LO; Nayak, S; Tammara, B, 2021) |
| "Patients with sickle cell anemia are at increased risk for osteoporosis, osteopenia, and osteomalacia." | ( Eskiocak, Ö; İlhan, G; Yılmaz, MÖ, 2022) |
| "Pregnancy in sickle cell disease is fraught with many complications including pre-eclampsia (PE) and intrauterine growth restriction (IUGR)." | ( Adeyemo, TA; Afolabi, BB; Babah, OA; Ezeaka, CV; Nwaiwu, O; Odukoya, OO; Ogunnaike, BA; Oshodi, YA, 2021) |
| "Sickle cell disease is associated with lower selenium levels, and the serum selenium level is inversely associated with haemolysis in SCD." | ( Henderson, GD, 2022) |
| "Sickle cell disease is a progressively debilitating genetic condition that affects red blood cells and can result in a variety of serious medical complications, reduced life expectancy, and diminished quality of life." | ( Fiori, A; Grady, A; Nysenbaum, J; Patel, D, 2021) |
| "Sickle cell disease is the most common monogenetic disorder worldwide." | ( Afolabi, BB; Aliyu, AU; Garba, SR; Kalejaiye, OO; Makwe, CC; Osunkalu, VO; Soibi-Harry, AP, 2021) |
| "Sickle cell disease is characterized by the painful recurrence of vaso-occlusive events." | ( Asmal, M; Aygun, B; Bonner, M; Goyal, S; Kanter, J; Kasow, KA; Kim, D; Krishnamurti, L; Kwiatkowski, JL; Lynch, J; Mapara, MY; Miller, A; Pierciey, FJ; Ribeil, JA; Rifkin-Zenenberg, S; Thompson, AA; Tisdale, JF; Walters, MC; Zhang, X, 2022) |
| "Sickle cell disease is the most widespread genetic disease in the world." | ( Baurain, M; Benghiat, S; Djomo Tamchom, D; Essola, B; Kapessidou, P; Kuitchet, A; Ndikontar, R; Nga Nomo, S; Van Obbergh, L, 2022) |
| "Sickle cell disease is the number one genetic disease in France in terms of the number of children diagnosed each year in the neonatal period." | ( Girot, R, 2022) |
| "Sickle cell anemia is a disease that develops episodes of acute pain and multiple organ dysfunction that can affect the growth hormone/insulin-like growth factor 1 (GH/IGF-1) axis." | ( Costa-Júnior, DAD; da Silva, CM; Santos, APP; Velloso-Rodrigues, C, 2022) |
| "Sickle cell anemia is a type of hemoglobinopathy characterized by a specific mutation in the beta globin gene with the consequent generation of an unstable hemoglobin that crystallizes in a state of hypoxia." | ( Benavides-Benítez, E; Bernal, JE; Briceño-Balcázar, I; Díaz-Matallana, M; Márquez-Benítez, Y; Martínez-Lozano, JC, 2021) |
| "Sickle cell disease is prevalent in large numbers of patients in the United States and has a significant global impact." | ( Achebe, MO; Burns, RB; Kanjee, Z; Smith, WR, 2022) |
| "Sickle cell anemia is of prime importance because of its high prevalence, morbimortality and the absence of curative treatments." | ( Bangaru, S; John, J; John, NA; Sabitha Rani, SS; Vamshidhar, IS, 2022) |
| "Sickle cell disease is an emerging anemia in Europe leading to high morbidity with severe acute complications requiring hospital admission and chronic consequences." | ( Adan-Pedroso, R; Astigarraga, I; de Pedro Olabarri, J; Del Orbe-Barreto, RA; Echebarria-Barona, A; Garcia-Ariza, M; Gonzalez-Urdiales, P; Lopez-Almaraz, R; Reparaz, P; Serrano, I; Vara-Pampliega, M, 2022) |
| "Sickle cell anemia is a class of hemoglobinopathy common in Sub-Saharan Africa." | ( Atolani, O; Awosika, A; Banerjee, P; Elemo, GN; Erukainure, OL; Ezeanyanaso, CS; Nwachukwu Nicholas-Okpara, VA; Okafor, JNC; Omowunmi, O; Preissner, R; Shode, F, 2022) |
| "Sickle cell disease is an inherited blood disorder afflicting an estimated 100,000 individuals in the United States and over 20 million people worldwide." | ( Lee, MT; Ogu, UO, 2022) |
| "Sickle cell disease is a common and highly morbid genetic condition that is characterized by multi-system involvement, including numerous cutaneous manifestations." | ( Dick, A; Khachemoune, A; Schwartzman, G, 2023) |
| "Sickle cell disease is a common and highly morbid genetic condition that is characterized by multi-system involvement, including numerous cutaneous manifestations." | ( Dick, A; Khachemoune, A; Schwartzman, G, 2023) |
| "Sickle cell disease is a common and highly morbid genetic condition that is characterized by multi-system involvement, including numerous cutaneous manifestations." | ( Dick, A; Khachemoune, A; Schwartzman, G, 2023) |
| "Sickle cell disease is the commonest genetic disorder in Nigeria, affecting 2-3% of an estimated population of 160 million people." | ( Aiyelokun, OE; Akinsola, OJ; Davies, NO; Ogbenna, AA; Olowoselu, FO; Osunkalu, VO; Taiwo, IA, 2022) |
| "Sickle cell disease is the commonest genetic disorder in Nigeria, affecting 2-3% of an estimated population of 160 million people." | ( Aiyelokun, OE; Akinsola, OJ; Davies, NO; Ogbenna, AA; Olowoselu, FO; Osunkalu, VO; Taiwo, IA, 2022) |
| "Sickle cell anemia is an inherited blood disorder caused due to a point mutation at the sixth codon of the ?-globin gene of both alleles." | ( Ghaju, S; Khadayat, K; Manandhar, T; Marasini, BP; Shrestha, R, 2022) |
| "Sickle cell disease is an inherited haematological condition with life-threatening consequences." | ( Brecht, ML; Jacob, E; Lee, E; Mawali, AA; Nasiri, YA; Nyamathi, A; Omari, OA; Robbins, W, 2023) |
| "Sickle cell disease is the consequence of a single point mutation on the surface of the β chains of the hemoglobin molecule leading to the formation of rigid polymers that disrupt circulation." | ( Bishop, MF; Ferrone, FA, 2023) |
| "Sickle cell disease is the most common inherited pathological haemoglobinopathy." | ( Jacob, SA; Kanter, J; Talati, R, 2023) |
| "Sickle cell anemia is a genetic disorder that affects hemoglobin leading to the production of an abnormal hemoglobin, called HbS." | ( Connes, P; Nader, E, 2023) |
| Excerpt | Reference |
|---|
| "One subject with sickle cell anemia displayed a distinctive auditory profile that we treat separately." | ( Orchik, DJ; Sharp, M, 1978) |
| "Seven patients with sickle cell anemia were treated with oxymetholone for at least 2 mo." | ( Alexanian, R; Nadell, J, 1975) |
| "Six patients with sickle cell anemia were treated with sodium cyanate (30 mg/kg/day)." | ( Bedine, M; Charache, S; Duffy, TP; Jander, N; Morrell, R; Scott, JC, 1975) |
| "Strategies for the treatment of sickle cell anemia and beta-thalassemia are founded on the knowledge that these disorders result from structural or functional defects in an adult gene for which an intact fetal counterpart exists." | ( Stamatoyannopoulos, JA, 1992) |
| "Patients with sickle cell anemia were treated with daily doses of hydroxyurea, to assess pharmacokinetics, toxicity, and increase in fetal hemoglobin (Hb) production in response to the drug." | ( Ballas, SK; Charache, S; Dover, GJ; Eckert, S; Koshy, M; Milner, PF; Moore, RD; Orringer, EP; Phillips, G; Platt, OS, 1992) |
| "Three sickle cell anemia patients were treated with escalating doses of intravenous rhEpo and, subsequently, with daily oral hydroxyurea." | ( Brugnara, C; Bunn, HF; Dover, GJ; Goldberg, MA; Lacroix, L; Schapira, L, 1992) |
| "In a pilot study, 15 patients with sickle cell anemia (SS) and one patient with SB thalassemia in vaso-occlusive crisis were treated with the Patient-Controlled Analgesia (PCA) technique using a Pharmacia Deltec Programmable pump (CADD PCA)." | ( Castro, O; Finke, H; McPherson, E; Perlin, E; Pittman, J, 1990) |
| "Five patients with sickle cell anemia were treated with hydroxyurea (HU), in hopes of augmenting their production of fetal hemoglobin." | ( Charache, S; Dover, GJ; Moore, JW; Moyer, MA, 1987) |
| "To determine its effect in sickle cell anemia, we treated two patients with a total of four, 5-d courses (50 mg/kg per d, divided into three oral doses)." | ( Beardsley, GP; Dover, G; Miller, B; Nathan, DG; Orkin, SH; Platt, OS, 1984) |
| "Two 19-year-old men with sickle cell anemia and hypogonadism had hypothalamic dysfunction that responded to oral clomiphene therapy." | ( Embury, SH; Kaplan, SL; Landefeld, CS; Schambelan, M, 1983) |
| "Eight patients with sickle cell anemia were treated for acute painful crises with DDAVP and intravenous fluids; five were treated with placebo and the same regimen of fluid administration." | ( Charache, S; Moyer, MA; Walker, WG, 1983) |
| "A 42-year-old woman with sickle cell anemia and proliferative retinopathy underwent neodymium-YAG laser therapy for a taut posterior hyaloid membrane causing peripapillary and peripheral traction detachment of the retina." | ( Goldberg, MF; Jampol, LM; Jednock, N, 1983) |
| "The lack of effective therapy of sickle cell anemia has prompted investigation of a large number of antisickling agents." | ( Balcerzak, SP; Bishop, JN; Grever, MR; Segal, ML; Sing, DE, 1982) |
| "A 2-year-old boy with sickle cell anemia had a massive, fatal hemolytic reaction after administration of an intravenous dose of ceftriaxone." | ( Bernini, JC; Buchanan, GR; Mustafa, MM; Sutor, LJ, 1995) |
| "Priapism secondary to sickle cell anemia has been treated with a variety of therapeutic regimens." | ( Guss, SP; Levine, LA, 1993) |
| "We report four sickle cell anemia patients who have received multiple blood transfusions and have been non-compliant on Desferal chelation therapy." | ( Flyer, MA; Haller, JO; Sundaram, R, 1993) |
| "We treated five subjects who have sickle cell anemia with oral clotrimazole, a specific Gardos channel inhibitor." | ( Alper, SL; Armsby, CC; Brugnara, C; Gee, B; Kurth, S; Platt, OS; Rifai, N; Sakamoto, M, 1996) |
| "Use of hydroxyurea (HU) to treat sickle cell disease is usually associated with increments in fetal hemoglobin (Hb F) production; however, in vitro studies show that HU may also induce hemoglobin denaturation." | ( Aguinaga, MP; Kopsombut, P; Roa, D; Turner, EA, 1997) |
| "We have treated 9 patients with sickle cell anemia (SS) with hydroxyurea (HU)." | ( Gu, LH; Hillen, HF; Huisman, TH; Saleh, AW; Velvis, HJ, 1997) |
| "A patient being treated for sickle cell disease with hydroxyurea (1 g/d) conceived, and drug treatment was discontinued at nine weeks gestational age." | ( Diav-Citrin, O; Hunnisett, L; Koren, G; Sher, GD, 1999) |
| "Strategies to treat sickle cell anemia since the early times of the disease state discovery in 1910, has focussed mainly on prophylactic measures to alleviate the painful crises." | ( Mehanna, AS, 2001) |
| "A seven-year-old boy with sickle cell anemia was admitted to the emergency department with severe pain unresponsive to high doses of oral acetaminophen; subsequently, intravenous codeine phosphate was administered." | ( Al Mohaimeed, SA; Zolezzi, M, 2001) |
| "CLT has been in clinical trials for the treatment of sickle cell disease, diarrhea and ameliorates the symptoms of rheumatoid arthritis." | ( Christophersen, P; Jensen, BS; Olesen, SP; Strøbaek, D, 2001) |
| "Specific treatment of sickle cell disease with hydroxyurea should be considered in cases with significant abnormalities of myocardial perfusion." | ( Acar, P; de Montalembert, M; Dulac, Y; Maunoury, C, 2003) |
| "Hydroxyurea treatment of sickle cell anemia patients leads to clinical improvement and reduces the incidence of vaso-occlusive episodes." | ( Covas, DT; de Lucena Angulo, I; Vianna Bonini Palma, P; Zago, MA, 2004) |
| "Blood samples from 15 sickle cell anemia patients were analyzed before and during treatment with hydroxyurea." | ( Covas, DT; de Lucena Angulo, I; Vianna Bonini Palma, P; Zago, MA, 2004) |
| "Hydroxyurea is a relatively new treatment for sickle cell disease." | ( King, SB, 2004) |
| "Hydroxyurea is increasingly used in the treatment of sickle cell disease (SCD) although there is little evidence on how best to monitor treatment and compliance." | ( Awogbade, M; Dalton, RN; Dick, M; Height, SE; Inusa, B; O'Driscoll, S; Okpala, I; Rees, DC; Thein, SL; Turner, C, 2005) |
| "Developments in the treatment of sickle cell disease (SCD) have not kept pace with advances in understanding the pathophysiology of this haemoglobinopathy." | ( Okpala, I, 2006) |
| "This report summarizes treatment of sickle cell disease and aplastic anemia by pediatric hematologists from 15 LIC who participate in the Monza International School of Pediatric Hematology/Oncology (MISPHO)." | ( de Reyes, G; Flores, A; Howard, SC; Machin, S; Masera, G; Navarrete, M; Nieves, R; Pacheco, C; Rodriguez, H; Svarch, E; Wilimas, JA, 2007) |
| "Hydroxyurea (HU) is useful for treating sickle cell anemia because of its ability to reduce some of the severe clinical events such as painful crises and acute chest syndrome." | ( Astier, A; Bachir, D; El Mahrab, M; Galacteros, F; Habibi, A; Huet, E; Hulin, A; Nzouakou, R, 2007) |
| "Recent progress in the treatment of sickle cell disease, in particular the use of hydroxyurea, has considerably modified the prognosis of this disease." | ( Ancel, PY; Bachir, D; Berthaut, I; de Larouziere, V; Galactéros, F; Girot, R; Guignedoux, G; Jouannet, P; Kirsch-Noir, F; Kunstmann, JM; Levy, L; Mandelbaum, J; Ravel, C, 2008) |
| "We report 2 children with sickle cell anemia who were diagnosed with DHTR and experienced a subsequent neurologic event in the course of treatment with corticosteroids." | ( Bertrand, Y; Elenga, N; Galambrun, C; Kebaïli, K; Mialou, V; Pondarre, C, 2008) |
| "We report a Saudi boy with sickle cell anemia, who developed acute MOFS following anaphylaxis to ceftriaxone administration." | ( Al-Aidaros, MA; Al-Harbi, DL; Al-Hawsawi, ZM; Turkistani, WA, 2010) |
| "Two patients presenting homozygous hemoglobin S disease died due to septicemia due to non-compliance with antibiotic therapy in one case and severe anemia in one case." | ( Cotton, F; Dedeken, L; Dresse, MF; Ferster, A; Gulbis, B; Heijmans, C; Ketelslegers, O; Lê, PQ; Vanderfaeillie, A; Vermylen, C; Vertongen, F, 2010) |
| "Stroke occurs in 5-10% of children with sickle cell anemia (SCA) and has a high (>50%) risk of recurrence without therapy." | ( Alvarez, O; Helms, RW; Hilliard, L; Iyer, RV; Miller, ST; Mortier, NA; Rogers, ZR; Schultz, WH; Scott, JP; Waclawiw, M; Ware, RE; Yovetich, N, 2011) |
| "Stroke is a devastating complication of sickle cell anemia (SCA) with high recurrence if untreated." | ( Helms, RW; Ware, RE, 2012) |
| "Sixty sickle cell anemia children (5-18 years) with more than three episodes of vasoocclusive crises or blood transfusions per year were randomized to receive HU (n = 30) or placebo (n = 30) therapy." | ( Bhatnagar, M; Desai, S; Jain, DL; Lodha, A; Sarathi, V, 2012) |
| "Our results show that DNA damage in sickle cell anemia is associated not only with treatment with HU but also with genotype." | ( Bandeira, IC; Barbosa, MC; da Silva Rocha, LB; Dias Elias, DB; Gonçalves, RP, 2012) |
| "Hydroxyurea (HU) is highly effective treatment for sickle cell disease (SCD)." | ( Cohen, HW; Driscoll, MC; Giardina, PJ; Green, NS; Mullen, C; Oyeku, SO; Pashankar, F; Racine, AD; Trachtman, R; Velazco, N, 2013) |
| "Hydroxyurea therapy in sickle cell anemia patients maintains fungal species balance in oral cavity." | ( Braga, JA; Brighenti, FL; Figueiredo, MS; Koga-Ito, CY; Pereira, DF; Salvia, AC, 2013) |
| "High-volume providers (those who treat more than 1 sickle cell disease patient per week), were less likely to redose opioids within 30 minutes for inadequate analgesia (risk ratio 0." | ( Chow, A; DeBaun, MR; Glassberg, JA; Harper, K; Haywood, C; Richardson, LD; Tanabe, P, 2013) |
| "In persons with sickle cell anemia, preoperative transfusion therapy to increase hemoglobin levels to 10 g/dL is strongly recommended with a moderate strength recommendation to maintain sickle hemoglobin levels of less than 30% prior to the next transfusion during long-term transfusion therapy." | ( Afenyi-Annan, AN; Ballas, SK; Buchanan, GR; Fulwood, R; Goldsmith, JC; Hassell, KL; Horton, A; James, AH; John-Sowah, J; Jordan, L; Lanzkron, SM; Lottenberg, R; Murad, MH; Ortiz, E; Savage, WJ; Tanabe, PJ; Ware, RE; Yawn, BP, 2014) |
| "We evaluated 10 patients with sickle cell anemia (SCA) treated with hydroxyurea (HU) and 13 SCA patients without this treatment." | ( Brunetta, DM; Covas, DT; De Santis, GC; Oliveira de Oliveira, LC; Silva-Pinto, AC, 2015) |
| "Adults with sickle cell anemia (HbSS) are inconsistently treated with hydroxyurea." | ( Allen, D; Coles, WA; Fitzhugh, CD; Hsieh, MM; Minniti, CP; Ring, M; Rodgers, GP; Schechter, AN; Seamon, C; Taylor, JG; Tisdale, JF; Zhao, X, 2015) |
| "Among children and adults with sickle cell anemia, the median number of pain crises over 48 weeks was lower among those who received oral therapy with l-glutamine, administered alone or with hydroxyurea, than among those who received placebo, with or without hydroxyurea." | ( Bellevue, R; Blake, OA; Gordeuk, VR; Guillaume, E; Hsu, LL; Kanter, J; Lanzkron, S; Lasky, JL; Miller, ST; Neumayr, LD; New, TN; Niihara, Y; Osunkwo, I; Panosyan, EH; Razon, RL; Sadanandan, S; Sarnaik, S; Sieger, L; Smith, WR; Stark, CW; Tran, LT; Vichinsky, EP; Viswanathan, K, 2018) |
| "Emergency treatments of sickle cell disease are frequent." | ( Anani, L; Baglo, T; Dodo, R; Mehou, J; Zohoun, A, 2018) |
| "A 49-year-old woman with sickle cell anemia (Hemoglobin SS) was admitted for the treatment of a vaso-occlusive crisis." | ( Arlet, JB; Flamarion, E; Khellaf, M; Michon, A; Passeron, A; Pouchot, J; Ranque, B; Saada, N, 2019) |
| "Options for the treatment of sickle cell disease are increasing." | ( Kimrey, S; Saving, KL, 2020) |
| "Food and Drug Administration to treat sickle cell disease (SCD) in November 2019." | ( Gordeuk, VR; Han, J; Saraf, SL, 2020) |
| "Hydroxyurea, indicated for managing sickle cell anemia (SCA), and L-glutamine, indicated for treating sickle cell disease (SCD), were the only pharmacotherapeutic options in this patient population before the approval of crizanlizumab by the U." | ( Gordeuk, VR; Han, J; Saraf, SL, 2020) |
| "Hydroxyurea is an efficacious treatment for sickle cell disease (SCD), but adoption is low among individuals with SCD." | ( Badawy, SM; Calhoun, C; Hankins, JS; Hodges, JR; Khan, H; King, A; Luo, L; Norell, S; Nwosu, C; Phillips, SM; Porter, J; Rojas Smith, L; Tanabe, P; Treadwell, M, 2020) |
| "The issue of treating sickle cell disease with drugs that increase hemoglobin oxygen affinity has come to the fore with the US Food and Drug Administration approval in 2019 of voxelotor, the only antisickling drug approved since hydroxyurea in 1998." | ( Best, RB; Bunn, HF; Cellmer, T; Conrey, A; Dunkelberger, EB; Eaton, WA; Glass, KE; Harper, J; Henry, ER; Li, Q; Metaferia, B; Thein, SL, 2021) |
| "Data on a total of 100 patients with sickle cell anemia were analyzed; 60 (60%) were being treated with hydroxyurea." | ( Appiah-Kubi, A; Aygun, B; Dhar, A; Gruber, D; Leung, TM; Mitchell, E; Serigano, O, 2021) |
| "Blood transfusion (BT) is essential in treating sickle cell disease (SCD); however, it leads to iron overload (IO) and oxidative stress." | ( Abdelfattah, SN; Abdelhalim, DA; El-Saeed, GSM; Elbostany, EA; Elghoroury, EA; Rashad, AA; Rasheed, EA; Salama, II; Salama, N; Thabet, EH, 2023) |
| "Although the prevalence of sickle cell anemia is high in Haiti, treatment with hydroxyurea (HU) is uncommon." | ( Canarie, MF; Faustino, EVS; Joseph, W; Mondesir, W; Paul-Hanna, M, 2022) |
| "The severity of sickle cell anemia is influenced by modifying factors, such as levels of fetal hemoglobin (HbF), the co-inheritance of alphathalassemia, or treatment with hydroxyurea." | ( Costa-Júnior, DAD; da Silva, CM; Santos, APP; Velloso-Rodrigues, C, 2022) |
| "Given the complex pathology of sickle cell anemia (SCA) and low adherence to hydroxyurea (HU) treatment, there is a need to seek parameters that identify recent changes in patient status." | ( Fogliatto, LM; Jahnke, VS; Lessa, CLM; Moreira, ID; Rocha, GLG; Rotta, LN; Schmitz, LD; Werlang, MC, 2022) |
| "DISEASE MODIFYING TREATMENTS FOR SICKLE CELL DISEASE." | ( Lionnet, F; Pondarré, C, 2023) |
| "The disease burden of sickle cell anemia (SCA) in sub-Saharan African (SSA) countries is substantial, with many children dying without an established diagnosis or proper treatment." | ( Blomberg, B; Hume, HA; John, CC; Kasirye, P; Nabaggala, C; Opoka, RO; Robberstad, B; Teigen, D; Ware, RE, 2023) |